GenMark Diagnostics CEO Sells $47,296 in Stock (GNMK)
GenMark Diagnostics (NASDAQ:GNMK) CEO Hany Massarany sold 3,925 shares of the company’s stock on the open market in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $12.05, for a total transaction of $47,296.25. Following the completion of the transaction, the chief executive officer now directly owns 247,693 shares of the company’s stock, valued at approximately $2,984,701. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Raymond James raised their price target on shares of GenMark Diagnostics to $15.00 in a research note to investors on Wednesday, October 2nd. Finally, analysts at Canaccord Genuity cut their price target on shares of GenMark Diagnostics from $18.00 to $14.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $14.67.
Shares of GenMark Diagnostics (NASDAQ:GNMK) traded up 2.82% during mid-day trading on Friday, hitting $12.38. 184,038 shares of the company’s stock traded hands. GenMark Diagnostics has a 52-week low of $7.55 and a 52-week high of $16.00. The stock has a 50-day moving average of $11.79 and a 200-day moving average of $12.25. The company’s market cap is $405.3 million.
GenMark Diagnostics (NASDAQ:GNMK) last announced its earnings results on Wednesday, August 7th. The company reported ($0.25) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.26) by $0.01. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $5.05 million. On average, analysts predict that GenMark Diagnostics will post $-0.90 earnings per share for the current fiscal year.
GenMark Diagnostics, Inc (NASDAQ:GNMK) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.